Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19: 72-80.Matozaki T, Murata Y, Okazawa H, Ohnishi H (2009) Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 19(2):72-80. doi:10.1016/j.tcb.2008. ...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域。该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/6... 查看全部>> 免费获取 收...
kappa/lambda bodies illustrates the power of the dual-targeting approach: A favorable safety profile and pharmacokinetics could be achieved in parallel to potent inhibition of the CD47-SIRP alpha interaction and effective cancer cell killing... K Masternak,Z Johnson,V Buatois,... - 《Cancer Immuno...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域.该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/620nm的比值为原始数据.本发明实现了...
CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit 中文名: 中文别名: CBNumber: CB215553531 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit化学性质 ...
Signal regulatory protein alpha (SIRP alpha) is a critical immune inhibitory receptor on macrophages, and its interaction with CD47 prevents autologous pha... C Wang,W Hui,K Ide,... - 《Cell Transplantation》 被引量: 29发表: 2011年 Efficacy of anti-CD47 antibody-mediated phagocytosis with mac...
CD47/SIRP alpha blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignanciesCD47BlinatumomabCombination therapyPhagocytosisNHLT cell immunotherapies are promising options in leukemia, among which the CD19/CD3-bispecific T cell engager antibody blinatumomab (MT103) ...
Interaction between target cell CD47 and the inhibitory macrophage receptor signal regulatory protein alpha (SIRPalpha) counteracts macrophage phagocytosis... M Olsson,P Bruhns,WA Frazier,... - 《Blood》 被引量: 169发表: 2005年 加载更多来源
CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPalpha /CD47 axis. The agent is a human SIRPalpha fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain...
VH) and antibody light chain variable domain (VL); the first antigen binding domain is the antibody variable domain capable of realizing the specific binding of the CD47; the second antigen binding domain is the antibody variable domain capable of realizing the specific binding of the SIRP alpha...